Stock Research for CYTR

CYTR

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

CYTR Stock Chart & Research Data

The CYTR chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the CYTR chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


CYTR Due diligence Resources & Stock Charts

The CYTR stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View CYTR Detailed Price Forecast - CNN Money CNN View CYTR Detailed Summary - Google Finance
Yahoo View CYTR Detailed Summary - Yahoo! Finance Zacks View CYTR Stock Research & Analysis - Zacks.com

Stock Analysis

TradeIdeas View CYTR Trends & Analysis - Trade-Ideas Barrons View CYTR Major Holders - Barrons
NASDAQ View CYTR Call Transcripts - NASDAQ Seeking View CYTR Breaking News & Analysis - Seeking Alpha
Spotlight View CYTR Annual Report - CompanySpotlight.com OTC Report View CYTR OTC Short Report - OTCShortReport.com
TradeKing View CYTR Fundamentals - TradeKing Charts View CYTR SEC Filings - Bar Chart
WSJ View Historical Prices for CYTR - The WSJ Morningstar View Performance/Total Return for CYTR - Morningstar
MarketWatch View the Analyst Estimates for CYTR - MarketWatch CNBC View the Earnings History for CYTR - CNBC
StockMarketWatch View the CYTR Earnings - StockMarketWatch MacroAxis View CYTR Buy or Sell Recommendations - MacroAxis
Bullish View the CYTR Bullish Patterns - American Bulls Short Pains View CYTR Short Pain Metrics - ShortPainBot.com

Social Media Mentions

StockTwits View CYTR Stock Mentions - StockTwits PennyStocks View CYTR Stock Mentions - PennyStockTweets
Twitter View CYTR Stock Mentions - Twitter Invest Hub View CYTR Investment Forum News - Investor Hub
Yahoo View CYTR Stock Mentions - Yahoo! Message Board Seeking Alpha View CYTR Stock Mentions - Seeking Alpha


Financial & Transaction Holdings

SECform4 View Insider Transactions for CYTR - SECform4.com Insider Cow View Insider Transactions for CYTR - Insider Cow
CNBC View CYTR Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for CYTR - OTC Markets
Yahoo View Insider Transactions for CYTR - Yahoo! Finance NASDAQ View Institutional Holdings for CYTR - NASDAQ


Stock Charts

FinViz View CYTR Stock Insight & Charts - FinViz.com StockCharts View CYTR Investment Charts - StockCharts.com
BarChart View CYTR Stock Overview & Charts - BarChart Trading View View CYTR User Generated Charts - Trading View




Latest Financial News for CYTR


CytRx Corporation's Subsidiary, Centurion BioPharma Corporation's Albumin Companion Diagnostic (ACDx), Could Be The First To Personalize Medicine For Albumin-Based Drug Delivery Systems
Posted on Tuesday March 12, 2019

LOS ANGELES, March 12, 2019 /PRNewswire/ -- CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology treatment and diagnostics, and its private, wholly-owned subsidiary Centurion BioPharma Corporation, today announced the publication of peer reviewed, scientific research for its Albumin Companion Diagnostic (ACDx). The article, titled "Development of a Novel Imaging Agent for Determining Albumin Uptake in Solid Tumors," has been published online in Nuclear Medicine and Molecular Imaging.  The abstract may be found and the full article purchased online at https://doi.org/10.1007/s13139-019-00587-w.


CytRx Corporation Leads Revival of Cytotoxic Therapies with LADR™ Technology Targeting Delivery Directly to the Tumor
Posted on Wednesday February 13, 2019

LOS ANGELES, Feb. 13, 2019 /PRNewswire/ -- CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology, and its private, wholly-owned subsidiary Centurion BioPharma Corporation, today announced the publication of peer reviewed, scientific research for LADR-7 (AE-Keto-Sulf07), one of its lead LADR™ (Linker Activated Drug Release) candidates.  The article, entitled "Novel auristatin E-based albumin-binding prodrugs with superior anticancer efficacy in vivo compared to the parent compound" to be published in the Journal of Controlled Release, a leading journal for drug delivery on February 28, 2019.  The abstract may be found and full article purchased online at  https://www.sciencedirect.com/journal/journal-of-controlled-release/vol/296.


CytRx Corporation Highlights Majority of Cancer Patients Do Not Have Targetable Genetic Mutations and Are Therefore Candidates for Chemotherapy
Posted on Monday February 11, 2019

LOS ANGELES, Feb. 11, 2019 /PRNewswire/ -- CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology, today highlighted comments from an OncLive® article dated February 1, 2019 that an estimated majority of oncology patients do not have targetable genetic mutations that would make them eligible for targeted treatment.


CytRx Corporation Highlights Positive Results from Full Data Set of Phase 2/3 Clinical Trial in Niemann Pick Disease Type C (NPC) Conducted by Arimoclomol Licensee Orphazyme A/S
Posted on Wednesday February 06, 2019

LOS ANGELES, Feb. 6, 2019 /PRNewswire/ -- CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology, highlighted positive Phase 2/3 clinical trial data from arimoclomol licensee Orphazyme A/S (ORPHA.CO). Orphazyme is currently developing arimoclomol in four different indications, including amyotrophic lateral sclerosis (ALS), Niemann-Pick disease Type C (NPC), Gaucher disease and sporadic Inclusion Body Myositis (sIBM).


Stock Market & Investing Books

Enter a stock symbol to view the stock details.